REFERENCES
1. Sipos D, Raposa BL, Freihat O, et al. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers. 2025;17:146.
2. Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives. Cancers. 2022;14:443.
3. Narsinh KH, Perez E, Haddad AF, et al. Strategies to improve drug delivery across the blood-brain barrier for glioblastoma. Curr Neurol Neurosci Rep. 2024;24:123-39.
4. Stupp R, Weller M, Belanger K, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
5. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-12.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:2248-9.
7. Verhaak RG, Hoadley KA, Purdom E, et al. ; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
8. Mishchenko TA, Turubanova VD, Gorshkova EN, Krysko O, Vedunova MV, Krysko DV. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy. Front Immunol. 2023;14:1299064.
9. Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023;5:vdad009.
10. Manini I, Caponnetto F, Bartolini A, et al. Role of microenvironment in glioma invasion: what we learned from in vitro models. Int J Mol Sci. 2018;19:147.
11. White J, White MPJ, Wickremesekera A, Peng L, Gray C. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med. 2024;22:540.
12. Yekula A, Yekula A, Muralidharan K, Kang K, Carter BS, Balaj L. Extracellular vesicles in glioblastoma tumor microenvironment. Front Immunol. 2019;10:3137.
13. Clancy JW, D'Souza-Schorey C. Tumor-derived extracellular vesicles: multifunctional entities in the tumor microenvironment. Annu Rev Pathol. 2023;18:205-29.
14. Xin W, Pan Y, Wei W, et al. Preconditioned extracellular vesicles from hypoxic microglia reduce poststroke AQP4 depolarization, disturbed cerebrospinal fluid flow, astrogliosis, and neuroinflammation. Theranostics. 2023;13:4197-216.
15. Bhavsar V, Sahu A, Taware R. Stress-induced extracellular vesicles: insight into their altered proteomic composition and probable physiological role in cancer. Mol Cell Biochem. 2025;480:2025-41.
16. Xiang H, Bao C, Chen Q, et al. Extracellular vesicles (EVs)’ journey in recipient cells: from recognition to cargo release. J Zhejiang Univ Sci B. 2024;25:633-55.
17. Dusoswa SA, Horrevorts SK, Ambrosini M, et al. Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. J Extracell Vesicles. 2019;8:1648995.
18. Cifola I, Fratini F, Cardinali B, et al. miRNome and proteome profiling of small extracellular vesicles secreted by human glioblastoma cell lines and primary cancer stem cells. Biomedicines. 2022;10:1886.
19. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. ; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
20. Kang T, Atukorala I, Mathivanan S. Biogenesis of extracellular vesicles. Subcell Biochem. 2021;97:19-43.
21. Musicò A, Zendrini A, Reyes SG, et al. Extracellular vesicles of different cellular origin feature distinct biomolecular corona dynamics. Nanoscale Horiz. 2024;10:104-12.
22. Heidarzadeh M, Zarebkohan A, Rahbarghazi R, Sokullu E. Protein corona and exosomes: new challenges and prospects. Cell Commun Signal. 2023;21:64.
23. Tóth EÁ, Turiák L, Visnovitz T, et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles. 2021;10:e12140.
24. Mishchenko TA, Olajide OJ, Gorshkova EN, Vedunova MV, Krysko DV. Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy. Trends Cancer. 2025;11:430-2.
25. Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21:190-202.
26. Wang X, Qiao D, Chen L, et al. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 2019;18:182.
27. Wang Q, Hu X, Hu B, et al. Tumor evolution of glioma-intrinsic gene expression subtype associates with immunological changes in the microenvironment. Cancer Cell. 2017;32:42-56.e6.
28. Schnöller LE, Piehlmaier D, Weber P, et al. Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. Radiat Oncol. 2023;18:51.
29. Arthurs AL, Keating DJ, Stringer BW, Conn SJ. The suitability of glioblastoma cell lines as models for primary glioblastoma cell metabolism. Cancers. 2020;12:3722.
30. Vedunova M, Turubanova V, Vershinina O, et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Dis. 2022;13:1062.
31. Sladowski D, Steer SJ, Clothier RH, Balls M. An improved MTT assay. J Immunol Methods. 1993;157:203-7.
32. Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2014;3:23430.
33. Karimova M, Ponziani G, Vardanyan D, et al. Cryogenic electron microscopy of extracellular vesicles from temozolomide-treated glioblastoma cells reveals great morphological heterogeneity. Nanomaterials. 2026;16:685.
34. Sbarigia C, Tacconi S, Mura F, Rossi M, Dinarelli S, Dini L. High-resolution atomic force microscopy as a tool for topographical mapping of surface budding. Front Cell Dev Biol. 2022;10:975919.
35. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-5.
36. Potenza F, Cufaro MC, Di Biase L, et al. Proteomic analysis of marinesco-sjogren syndrome fibroblasts indicates pro-survival metabolic adaptation to SIL1 loss. Int J Mol Sci. 2021;22:12449.
37. Madonna R, Pieragostino D, Cufaro MC, et al. Ponatinib induces vascular toxicity through the Notch-1 signaling pathway. J Clin Med. 2020;9:820.
38. Pieragostino D, Lanzini M, Cicalini I, et al. Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for Neurotrophic Keratopathy. Sci Rep. 2022;12:1229.
39. Perez-Riverol Y, Bandla C, Kundu DJ, et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 2025;53:D543-53.
40. Mishchenko TA, Balalaeva IV, Turubanova VD, et al. Chapter 8 - gold standard assessment of immunogenic cell death induced by photodynamic therapy: from in vitro to tumor mouse models and anti-cancer vaccination strategies. Methods Cell Biol. 2024;183:203-64.
41. Network TC. Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2013;494:506.
42. Eisenbarth D, Wang YA. Glioblastoma heterogeneity at single cell resolution. Oncogene. 2023;42:2155-65.
43. Jeuken JW, Cornelissen SJ, Vriezen M, et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007;87:1055-65.
44. Anan M, Del Maestro RF, Hata N, Fujiki M. O6 -methylguanine methyltransferase promoter methylation status of glioblastoma cell line clonal population. Neuropathology. 2024;44:41-6.
45. Abe H, Natsumeda M, Okada M, et al. MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas. Front Oncol. 2019;9:1568.
46. Pu J, Yuan K, Tao J, et al. Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance. Discov Oncol. 2025;16:731.
47. Mol EA, Goumans MJ, Doevendans PA, Sluijter JPG, Vader P. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomedicine. 2017;13:2061-5.
48. Paget D, Checa A, Zöhrer B, et al. ; Oxford Acute Myocardial Infarction Study (OxAMI). Comparative and integrated analysis of plasma extracellular vesicle isolation methods in healthy volunteers and patients following myocardial infarction. J Extracell Biol. 2022;1:e66.
49. Grenhas M, Lopes R, Ferreira BV, Barahona F, João C, Carneiro EA. Size-exclusion chromatography: a path to higher yield and reproducibility compared to sucrose cushion ultracentrifugation for extracellular vesicle isolation in multiple myeloma. Int J Mol Sci. 2024;25:8496.
50. Berumen Sánchez G, Bunn KE, Pua HH, Rafat M. Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. Cell Commun Signal. 2021;19:104.
51. André-Grégoire G, Bidère N, Gavard J. Temozolomide affects extracellular vesicles released by glioblastoma cells. Biochimie. 2018;155:11-5.
52. Bandari SK, Purushothaman A, Ramani VC, et al. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 2018;65:104-18.
53. Ab Razak NS, Ab Mutalib NS, Mohtar MA, Abu N. Impact of chemotherapy on extracellular vesicles: understanding the chemo-EVs. Front Oncol. 2019;9:1113.
54. Garnier D, Meehan B, Kislinger T, et al. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol. 2018;20:236-48.
55. Simon T, Pinioti S, Schellenberger P, et al. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. Mol Cancer. 2018;17:132.
56. Casado S, Lobo MDVT, Paíno CL. Dynamics of plasma membrane surface related to the release of extracellular vesicles by mesenchymal stem cells in culture. Sci Rep. 2017;7:6767.
57. Mitani F, Hayasaka R, Hirayama A, Oneyama C. SNAP23-mediated perturbation of cholesterol-enriched membrane microdomain promotes extracellular vesicle production in Src-activated cancer cells. Biol Pharm Bull. 2022;45:1572-80.
58. Mukhopadhyay U, Mandal T, Chakraborty M, Sinha B. The plasma membrane and mechanoregulation in cells. ACS Omega. 2024;9:21780-97.
59. Choromańska A, Chwiłkowska A, Kulbacka J, et al. Modifications of plasma membrane organization in cancer cells for targeted therapy. Molecules. 2021;26:1850.
60. Lehrich BM, Liang Y, Fiandaca MS. Foetal bovine serum influence on in vitro extracellular vesicle analyses. J Extracell Vesicles. 2021;10:e12061.
61. Försönits AI, Tóth EÁ, Jezsoviczky S, et al. Improved accessibility of extracellular vesicle surface molecules upon partial removal of the protein corona by high ionic strength. J Extracell Vesicles. 2025;14:e70124.
62. Naryzhny S, Volnitskiy A, Kopylov A, et al. Proteome of glioblastoma-derived exosomes as a source of biomarkers. Biomedicines. 2020;8:216.
63. Hallal S, Russell BP, Wei H, et al. Extracellular vesicles from neurosurgical aspirates identifies chaperonin containing TCP1 subunit 6A as a potential glioblastoma biomarker with prognostic significance. Proteomics. 2019;19:e1800157.
64. Giuliani P, De Simone C, Febo G, et al. Proteomics studies on extracellular vesicles derived from glioblastoma: where do we stand? Int J Mol Sci 2024;25:9778.
65. Ma L, Li Y, Peng J, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015;25:24-38.
66. Minciacchi VR, You S, Spinelli C, et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget. 2015;6:11327-41.
67. Solvik TA, Nguyen TA, Tony Lin YH, et al. Secretory autophagy maintains proteostasis upon lysosome inhibition. J Cell Biol. 2022;221:e202110151.
68. Ma C, Nguyen HPT, Jones JJ, et al. Extracellular vesicles secreted by glioma stem cells are involved in radiation resistance and glioma progression. Int J Mol Sci. 2022;23:2770.
69. Kıyga E, Adıgüzel Z, Önay Uçar E. Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. Mol Biol Rep. 2022;49:8701-13.
70. Joshi AD, Botham RC, Schlein LJ, et al. Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget. 2017;8:80124-38.
71. Fianco G, Mongiardi MP, Levi A, et al. Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. Elife. 2017;6:e22593.
72. Hu X, Jiang C, Gao Y, Xue X. Human dendritic cell subsets in the glioblastoma-associated microenvironment. J Neuroimmunol. 2023;383:578147.
73. Adhikaree J, Franks HA, Televantos C, et al. Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines. Oncoimmunology. 2019;8:1593803.
74. van der Vos KE, Abels ER, Zhang X, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2016;18:58-69.
75. Zhang L, Yang J, Zhou Z, et al. A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity. Proc Natl Acad Sci U S A. 2025;122:e2427073122.
76. Madhu LN, Kodali M, Rao S, et al. Intranasal human NSC-derived EVs therapy can restrain inflammatory microglial transcriptome, and NLRP3 and cGAS-STING signalling, in aged hippocampus. J Extracell Vesicles. 2026;15:e70232.
77. Manni G, Gargaro M, Ricciuti D, et al. Amniotic fluid stem cell-derived extracellular vesicles educate type 2 conventional dendritic cells to rescue autoimmune disorders in a multiple sclerosis mouse model. J Extracell Vesicles. 2024;13:e12446.
78. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:24641.
